Reading AMRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AMRX free→Reading AMRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AMRX free→NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been steady, while risk is moderate and the sector backdrop is a headwind. Peer multiples imply a price about 35% below where it trades (it looks expensive on this basis); the read is fair, quality intact. Key factors to watch include guidance changes and sector trends, particularly how bellwethers perform. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $16.25. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $16 the market pays 18× p/e — above the 13× p/e peer median but in line with its own 18× history. That premium reflects a durable franchise our peer-anchored $12 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $16–$19. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 35% near-term growth, well above our forecast of about 7%. This describes what's priced in, not a forecast of the move.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.50x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.23 → $0.23 (+0.2% / 30d). 2 raised, 1 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 35.5% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$154.
How much price usually moves either way.
On a bad day, this stock has moved -$315.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,225.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Shareholder approval is important for Amneal. It helps them complete the deal and grow their biosimilars.
Confirms:The shareholder vote passes with over 75% approval for the deal.
Disproves:The shareholder vote does not reach the needed approval level.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Advances: Expand through M&A with Kashiv BioSciences
CREXONT gains support growth through M&A strategy.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 7, 2026, Amneal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$16.00 – $19.00 (median $17.00) · 3 analysts · as of 2026-05-20
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
AMRX Amneal Pharmaceuticals | Above typical Show detailsSector percentile: 89 of 100 | full | moderate |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 89 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 75 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 68 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 64 of 100 | fair | low |
4 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Amneal aims to expand its business through the acquisition of Kashiv BioSciences.
Focus on enhancing operating income through cost management and efficiency improvements.
Amneal aims to enhance cash flow from operating activities to support growth and operational needs.
Why it matters: Better cash flow would show improved efficiency. It would also help support future growth plans.
Confirms:Operating cash flow reported above $375 million for Q2 2026.
Disproves:Operating cash flow reported below $350 million for Q2 2026.
Why it matters: A drop in growth might show market saturation. It could also mean more competition in the Specialty segment.
Confirms:Specialty net revenue growth reported at 20% or higher for Q2 2026.
Disproves:Specialty net revenue growth reported below 20% for Q2 2026.
Why it matters: Strong revenue growth in Q2 would show good progress from Q1. It would also show the impact of the Kashiv deal.
Confirms:Q2 2026 net revenue is over $760 million. This shows growth compared to Q1.
Disproves:Q2 2026 net revenue reported below $720 million, showing a slowdown.
Advances: Expand through M&A with Kashiv BioSciences
CREXONT gains support growth through M&A strategy.
Advances: Expand through M&A with Kashiv BioSciences
Biosimilars and patches align with growth expansion goals.
Results of Operations and Financial Condition. On April 22, 2026, the Company issued a press release announcing its preliminary results for the first quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t…
Entry into a Material Definitive Agreement. Membership Interest Purchase Agreement On April 21, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Amneal”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Kashiv BioSciences, LLC (“Kashiv”), KB Seller Representative, LLC (the “Seller Representative”) and the equityholders of Kashiv named therein (the “Sellers”), pursuant to which, among other matters and on the terms and subject…
Unregistered Sales of Equity Securities. The information set forth in
Results of Operations and Financial Condition. On February 27, 2026, Amneal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Secu…